Abstract: FR-PO746
High Hepcidin Is Associated With the Progression of Coronary Artery Calcification in Patients With CKD
Session Information
- Hypertension and CVD: Clinical, Outcomes, Trials
November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Hypertension and CVD
- 1502 Hypertension and CVD: Clinical‚ Outcomes‚ and Trials
Authors
- Ko, Ye Eun, Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea (the Republic of)
- Koh, Hee Byung, Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea (the Republic of)
- Jhee, Jong Hyun, Division of Nephrology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea (the Republic of)
- Yoo, Tae-Hyun, Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea (the Republic of)
Background
Hepcidin is well known for its role in iron metabolism, but, its relationship with calcium metabolism had also been studied. In addition, a recent report showed a positive correlation between hepcidin level and the incidence of atherosclerotic disease. In hemodialysis population, elevated hepcidin level was related to increased cardiovascular outcome. The aim of this study is to investigate the association between hepcidin and coronary artery calcification progression in non-dialysis chronic kidney disease.
Methods
A total of 1,153 CKD (stage 1 to 5) patients were enrolled from the nationwide multicenter prospective observational cohort of KNOW-CKD (KoreaN Cohort Study for Outomes in Patients With Chronic Kidney Disease). Primary outcome was CAC progression, which was defined as annualized percentage change in CAC score: (percent change in CAC score + 1)＾(12/follow-up months)-1, of > 15%.
Results
The mean age of study subjects was 52.8±12.0 years and 673(59.8%) were male. During 4 year follow up, annualized percentage change in CAC score was 20.0±36.8 in study patients, 15.2±41.7 in group without CAC, 26.9±31.7 in patients with CAC score above 0. There were statistically significant differences in age (50.5±12.3, 56.7±9.9; P<0.001), gender (male 55.6%, 66.4%; P=0.001), DM status (19.6%, 38.4%; P<0.001), and hepcidin level at baseline (14.5±12.9, 16.3±15.4; P=0.04) between CAC non-progression and progression group. In multivariate logistic regression analysis, all patients and patients with baseline CAC score above 0 showed the association between elevation in log (hepcidin+1) and increased risk of CAC progression (OR, 1.74; 95% CI, 1.02-2.96; P=0.04, OR, 2.41; 95% CI, 1.08-5.37; P=0.03).
Conclusion
Hepcidin level may be an independent predictor of CAC progression in CKD patients.